NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress
May 19, 2026
Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory